Unable to connect, retrying...
Online collaborative whiteboard. Powerful, engaging with timer, emoji's, commenting and voting.
Search for RSS feeds

Drug Channels

Expert insights by Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system (RSS feed)

Feed:

Drug Channels News Roundup, April 2024: CVS’s Humira Stra...eens Specialty Update, Pharmacies vs. GoodRx, and Oncology Fun

Drug Channels News Roundup, April 2024: CVS’s Humira Stra...eens Specialty
Update, Pharmacies vs. GoodRx, and Oncology Fun

April is over, so it's time to hop into this month’s selection of noteworthy news: CVS Health’s formulary boosts a Humira biosimilar An insurer ditches buy-and-bill to save money for plans�...

https://feeds.feedblitz.com/~/886360400/0/drugchannels~Drug-Channels-News-Roundup-April-CVS%E2%80%99s-Humira-Strategy-White-Bagging-%E2%80%9CSavings%E2%80%9D-IRA-vs-Part-D-Plans-Walgreens-Specialty-Update.html

The Top 15 Specialty Pharmacies of 2023: Market Shares and Revenues at the Biggest PBMs, Health Plans, and Independents

The Top 15 Specialty Pharmacies of 2023: Market Shares and Revenues at
the Biggest PBMs, Health Plans, and Independents

Drug Channels Institute’s (DCI’s) latest analysis finds that participants in the specialty pharmacy market continue to get more diverse—although revenues remain highly concentrated. We h...

https://feeds.feedblitz.com/~/881347613/0/drugchannels~The-Top-Specialty-Pharmacies-of-Market-Shares-and-Revenues-at-the-Biggest-PBMs-Health-Plans-and-Independents.html

The Top Pharmacy Benefit Managers of 2023: Market Share and Trends for the Biggest Companies—And What’s Ahead

The Top Pharmacy Benefit Managers of 2023: Market Share and Trends for
the Biggest Companies—And What’s Ahead

Three is still the magic number for pharmacy benefit managers (PBMs). For 2023, nearly 80% of all equivalent prescription claims were processed by three companies: the Caremark business of CVS...

https://feeds.feedblitz.com/~/875555969/0/drugchannels~The-Top-Pharmacy-Benefit-Managers-of-Market-Share-and-Trends-for-the-Biggest-Companies%E2%80%94And-What%E2%80%99s-Ahead.html

Tales of the Unsurprised: U.S. Brand-Name Drug Prices Fell ...Sixth Consecutive Year—And Will Fall Further in 2024 (rerun)

Tales of the Unsurprised: U.S. Brand-Name Drug Prices Fell ...Sixth Consecutive Year—And Will Fall Further in 2024
(rerun)

This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: DRUG CHANNEL IMPLICATIONS OF THE INFLATION REDUCTION ACT . One important update: In the article be...

https://feeds.feedblitz.com/~/875123552/0/drugchannels~Tales-of-the-Unsurprised-US-BrandName-Drug-Prices-Fell-for-an-Unprecedented-Sixth-Consecutive-Year%E2%80%94And-Will-Fall-Further-in-rerun.html

The Big Three PBMs’ 2024 Formulary Exclusions: Biosimilar...CVS Health’s Weird Strategy, and the Insulin Shakeup (rerun)

The Big Three PBMs’ 2024 Formulary Exclusions: Biosimilar...CVS Health’s Weird Strategy, and the Insulin Shakeup
(rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: DRUG CHANNEL IMPLICATIONS OF THE INFLATION REDUCTION ACT . The 2024 formularies described below s...

https://feeds.feedblitz.com/~/874943387/0/drugchannels~The-Big-Three-PBMs%E2%80%99-Formulary-Exclusions-Biosimilar-Humira-Battles-CVS-Health%E2%80%99s-Weird-Strategy-and-the-Insulin-Shakeup-rerun.html

What CVS Pharmacy’s New Cost-Plus Reimbursement Approach ...Ms, Pharmacies, Plan Sponsors, and Prescription Prices (rerun)

What CVS Pharmacy’s New Cost-Plus Reimbursement Approach ...Ms, Pharmacies, Plan Sponsors, and Prescription Prices (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: DRUG CHANNEL IMPLICATIONS OF THE INFLATION REDUCTION ACT . For more on acquisition cost reimburs...

https://feeds.feedblitz.com/~/874870319/0/drugchannels~What-CVS-Pharmacy%E2%80%99s-New-CostPlus-Reimbursement-Approach-Means-for-PBMs-Pharmacies-Plan-Sponsors-and-Prescription-Prices-rerun.html

Drug Channels News Roundup, March 2024: My $0.02 of Carelon...Pharmacies, Shady AFPs, 340B Deception, and Lilly’s GLP-1 Ad

Drug Channels News Roundup, March 2024: My $0.02 of Carelon...Pharmacies, Shady AFPs, 340B Deception, and
Lilly’s GLP-1 Ad

It’s finally spring in Philadelphia, home of Drug Channels. Along with sunshine and fine weather, the vernal equinox has ushered in a crop of new and noteworthy stories: What the CarelonRx/Kro...

https://feeds.feedblitz.com/~/874459583/0/drugchannels~Drug-Channels-News-Roundup-March-My-of-CarelonRxKroger-CVS-ProviderOwned-Pharmacies-Shady-AFPs-B-Deception-and-Lilly%E2%80%99s-GLP-Ad.html